Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis

Inclusion criteria

• Children with a new diagnosis of Crohn's Disease and whose physician has not yet initiated corticosteroid treatment (10 Subjects):
• Clinical diagnosis within the previous 21 days
• Above age 7 and younger than age 18
• Signed informed consent statement and assent statement.
• Children with a new diagnosis of Ulcerative Colitis and whose physician has not yet initiated corticosteroid treatment (10 Subjects):
• Clinical diagnosis within the previous 21 days
• Above age 7 and younger than age 18
• Signed informed consent statement and assent statement.
• Children with Crohn's Disease whose physician has initiated Infliximab treatment for the first time (10 Subjects):
• Clinical diagnosis of Crohn's Disease
• Above age 7 and younger that age 18
• Signed informed consent statement and assent statement.
• Children with Ulcerative Colitis whose physician has initiated Infliximab treatment for the first time (10 Subjects):
• Clinical diagnosis of Ulcerative Colitis
• Above age 7 and younger than age 18
• Signed informed consent statement and assent statement.
• Healthy Controls (10 Subjects):
• Above age 7 and younger than age 18
• otherwise healthy, with no intercurrent illness as determined by a member of the study team using the eligibility checklist
• controls will be gender and age (± 2 years) matched to the patient groups described above
• Signed informed consent statement and assent statement

Exclusion criteria

• unwilling to give consent for this study.
• child with prior prescription and administration of Infliximab